ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism
Yanan Yang(Shanghai Medical College of Fudan University), Jonathan M. Kurie(The University of Texas MD Anderson Cancer Center), Jaime Rodriguez‐Canales(National Cancer Institute), Don L. Gibbons(The University of Texas MD Anderson Cancer Center), Christin Ungewiss(Fred Hutch Cancer Center), Ignacio I. Wistuba(The University of Texas MD Anderson Cancer Center), Lixia Guo(Mayo Clinic), Nishan Thilaganathan(The University of Texas MD Anderson Cancer Center), Young‐Ho Ahn(Ewha Womans University), Steven H. Lin(The University of Texas MD Anderson Cancer Center), Georgia McLendon(The University of Texas MD Anderson Cancer Center), Xin Liu(Beijing Radiation Center), Yulong Chen(Wuhan Polytechnic University), Xiaochao Tan(Tulane University), Chad J. Creighton(Baylor College of Medicine), David H. Peng(The University of Texas MD Anderson Cancer Center)
Cited by 113
Related Papers
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
|Neoplasia|2017|6.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
UALCAN: An update to the integrated cancer data analysis platform
|Neoplasia|2022|2.5k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k